{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:35:33Z","timestamp":1792175733714,"version":"4.4.0"},"reference-count":267,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13346-025-01947-0","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T16:28:40Z","timestamp":1755707320000},"page":"4367-4410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibody-conjugated polymer nanoparticles for brain cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"San San Amelia","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooi Leong","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athirah","family":"Bakhtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Chi-Lui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-0849","authenticated-orcid":false,"given":"Lay Hong","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"1947_CR1","unstructured":"Institute for Health Metrics and Evaluation. Global Health Data Exchange (GHDx). Institute for Health Metrics and Evaluation. 2023. Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed 9 Mar 2025."},{"key":"1947_CR2","unstructured":"Brain, other CNS and intracranial tumors incidence statistics. Cancer Research UK. CRUK; 2015. Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/brain-tumors\/incidence. Accessed 9 Mar 2025."},{"key":"1947_CR3","unstructured":"National Cancer Institute. Cancer of the Brain and Other Nervous System - Cancer Stat Facts. SEER. 2018. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/brain.html. Accessed 5 Mar 2025."},{"key":"1947_CR4","doi-asserted-by":"crossref","unstructured":"Liu X, Cheng LC, Gao TY, Luo J, Zhang C. The burden of brain and central nervous system cancers in Asia from 1990 to 2019 and its predicted level in the next twenty-five years. BMC Public Health. 2023;23(1).","DOI":"10.1186\/s12889-023-17467-w"},{"key":"1947_CR5","unstructured":"Types BT. Glioblastoma, Meningioma & More. Miamineurosciencecenter.com. 2020. Available from: https:\/\/miamineurosciencecenter.com\/en\/conditions\/brain-tumors\/types\/#meningioma. Accessed 22 Apr 2025."},{"key":"1947_CR6","unstructured":"John Hopkins Medicine. Meningioma. www.hopkinsmedicine.org. Available from: https:\/\/www.hopkinsmedicine.org. Accessed 22 Apr 2025."},{"key":"1947_CR7","unstructured":"Medulloblastoma. @macmillancancer. 2024. Available from: https:\/\/www.macmillan.org.uk\/cancer-information-and-support\/brain-tumor\/medulloblastoma. Accessed 25 Apr 2025."},{"key":"1947_CR8","doi-asserted-by":"crossref","unstructured":"Franceschi E, Frappaz D, Rud\u00e0 R, Hau P, Preusser M, Houillier C et al. Rare primary central nervous system tumors in adults: an overview. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.00996"},{"key":"1947_CR9","unstructured":"Bettegowda C. Metastatic Brain Tumors. www.hopkinsmedicine.org. Available from: https:\/\/www.hopkinsmedicine.org. Accessed 25 Apr 2025."},{"issue":"2","key":"1947_CR10","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3390\/ijms13021951","volume":"13","author":"SJ Diaz-Cano","year":"2012","unstructured":"Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci. 2012;13(2):1951\u20132011. https:\/\/doi.org\/10.3390\/ijms13021951","journal-title":"Int J Mol Sci"},{"key":"1947_CR11","unstructured":"Cancer Research UK. Jul. Grades of Brain and Spinal Cord Tumours| Cancer Research UK. www.cancerresearchuk.org.2023. Available from: https:\/\/www.cancerresearchuk.org. Accessed 12 2025."},{"key":"1947_CR12","unstructured":"Cancer Research UK. Mar. Types of brain tumors| Cancer Research UK. www.cancerresearchuk.org. Available from: https:\/\/www.cancerresearchuk.org. Accessed 5 2025."},{"key":"1947_CR13","doi-asserted-by":"crossref","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: Structure, regulation, and drug delivery. Signal Transduction and Targeted Therapy. 2023;8(1):1\u201327. Available from: https:\/\/www.nature.com\/articles\/s41392-023-01481-w","DOI":"10.1038\/s41392-023-01481-w"},{"issue":"2","key":"1947_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","volume":"31","author":"MM Patel","year":"2017","unstructured":"Patel MM, Patel BM. Crossing the Blood\u2013Brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109\u201333. https:\/\/doi.org\/10.1007\/s40263-016-0405-9","journal-title":"CNS Drugs"},{"issue":"2","key":"1947_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1208\/s12249-021-01928-9","volume":"22","author":"K Wiwatchaitawee","year":"2021","unstructured":"Wiwatchaitawee K, Quarterman JC, Geary SM, Salem AK. Enhancement of therapies for glioblastoma (GBM) using nanoparticle based delivery systems. AAPS PharmSciTech. 2021;22(2):71. https:\/\/doi.org\/10.1208\/s12249-021-01928-9","journal-title":"AAPS PharmSciTech"},{"key":"1947_CR16","doi-asserted-by":"crossref","unstructured":"Reilly KM. Brain Tumor Susceptibility: the Role of Genetic Factors and Uses of Mouse Models to Unravel Risk. Brain Pathology. 2009 Jan [cited 2019 Jun 6];19(1):121\u201331. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2761018\/","DOI":"10.1111\/j.1750-3639.2008.00236.x"},{"key":"1947_CR17","doi-asserted-by":"publisher","unstructured":"Shelton WJ, Zandpazandi S, Nix JS, Gokden M, Bauer M, Ryan KR, et al. Long-read sequencing for brain tumors. Front Oncol. 2024;14. https:\/\/doi.org\/10.3389\/fonc.2024.1395985","DOI":"10.3389\/fonc.2024.1395985"},{"key":"1947_CR18","doi-asserted-by":"crossref","unstructured":"Kayabolen A, Yilmaz E, Bagci-Onder T. IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications? Biomedicines. 2021;9(7):799. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34356864\/","DOI":"10.3390\/biomedicines9070799"},{"key":"1947_CR19","doi-asserted-by":"publisher","unstructured":"Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Molecular Cancer. 2025;24(1). Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12943-025-02267-0","DOI":"10.1186\/s12943-025-02267-0"},{"key":"1947_CR20","doi-asserted-by":"publisher","unstructured":"Skowron P, Farooq H, Cavalli FMG, Morrissy AS, Ly M, Hendrikse LD, et al. The transcriptional landscape of Shh Medulloblastoma. Nat Commun. 2021;12(1). https:\/\/doi.org\/10.1038\/s41467-021-21883-0","DOI":"10.1038\/s41467-021-21883-0"},{"issue":"3","key":"1947_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/nan.12259","volume":"42","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, et al. Recurrent mutations ofCD79BandMYD88are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2015;42(3):279\u201390. https:\/\/doi.org\/10.1111\/nan.12259","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1947_CR22","unstructured":"Fern\u00e1ndez-de Thomas RJ, De Jesus O, Munakomi S. Craniotomy. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560922\/"},{"key":"1947_CR23","doi-asserted-by":"publisher","unstructured":"Li K, Liang J, Niu H, Lan SY, Liang X, Zhao Y, et al. Effect comparison of neuroendoscopy versus microsurgery in the treatment of lateral ventricular tumors. Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1008291","DOI":"10.3389\/fonc.2023.1008291"},{"key":"1947_CR24","unstructured":"Surgery for brain tumors. Cancerresearchuk.org. 2023. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/brain-tumors\/treatment\/surgery\/remove-brain-tumor. Accessed 5 Mar 2025."},{"key":"1947_CR25","unstructured":"National Cancer Institute. Radiation Therapy to Treat Cancer. National Cancer Institute. 2019. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/radiation-therapy"},{"key":"1947_CR26","unstructured":"3-D conformal radiation -. Mayo Clinic. www.mayoclinic.org. [cited 2022 Apr 25]. Available from: https:\/\/www.mayoclinic.org. Accessed 12 Jul 2025."},{"key":"1947_CR27","unstructured":"Cancer Research UK. Radiotherapy treatment| Brain and spinal cord tumors| Cancer Research UK. Cancerresearchuk.org. 2019. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/brain-tumors\/treatment\/radiotherapy\/radiotherapy-treatment. Accessed 5 Mar 2025."},{"key":"1947_CR28","doi-asserted-by":"crossref","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Current Neuropharmacology. 2021;19(4):513\u201337. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8206461\/","DOI":"10.2174\/1570159X18666200626204005"},{"issue":"4","key":"1947_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/now185","volume":"19","author":"TT Batchelor","year":"2016","unstructured":"Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, et al. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-\u03b2 tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neurooncology. 2016;19(4):567\u201375. https:\/\/doi.org\/10.1093\/neuonc\/now185","journal-title":"Neurooncology"},{"key":"1947_CR30","doi-asserted-by":"publisher","unstructured":"Liu Sfeng, Li MJ, Liang B, Sun W, Shao Y, Hu X et al. Breaking the barrier: Nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment. Frontiers in Pharmacology. 2024;15. Available from: https:\/\/doi.org\/10.3389\/fphar.2024.1394816","DOI":"10.3389\/fphar.2024.1394816"},{"key":"1947_CR31","doi-asserted-by":"crossref","unstructured":"Anwer MS, Abdel-Rasol MA, El-Sayed WM. Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations. Clinical and Experimental Medicine. 2025 Apr 13 [cited 2025 Jul 12];25(1). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11994545\/","DOI":"10.1007\/s10238-025-01631-0"},{"key":"1947_CR32","doi-asserted-by":"publisher","unstructured":"Bai F, Deng Y, Li L, Lv M, Jamoliddin Razzokov, Xu Q et al. Advancements and challenges in brain cancer therapeutics. Exploration. 2024;4(6). Available from: https:\/\/doi.org\/10.1002\/EXP.20230177","DOI":"10.1002\/EXP.20230177"},{"key":"1947_CR33","unstructured":"PARP inhibitors. Cancerresearchuk.org. 2025. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/treatment\/targeted-cancer-drugs-immunotherapy\/parp-inhibitors"},{"issue":"16","key":"1947_CR34","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3390\/cancers16162852","volume":"16","author":"AB Jones","year":"2024","unstructured":"Jones AB, Tuy K, Hawkins CC, Quinn CH, Saad J, Gary SE, et al. Temozolomide and the PARP inhibitor niraparib enhance expression of natural killer group 2D ligand ULBP1 and Gamma-Delta T cell cytotoxicity in glioblastoma. Cancers. 2024;16(16):2852\u20132. https:\/\/doi.org\/10.3390\/cancers16162852","journal-title":"Cancers"},{"key":"1947_CR35","doi-asserted-by":"crossref","unstructured":"Elisavet Deligianni, Papanikolaou C, Evangelos Terpos, Souliotis VL, Elucidating DNA, Damage-Dependent. Immune System Activation. International Journal of Molecular Sciences. 26(12):5849\u20139. Available from: https:\/\/www.mdpi.com\/1422-0067\/26\/12\/5849","DOI":"10.3390\/ijms26125849"},{"issue":"5","key":"1947_CR36","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol (Toronto Ont). 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"1947_CR37","doi-asserted-by":"publisher","unstructured":"Huang C, Gustineli B, Barbuto A. Effect of temozolomide on dendritic cell vaccine for glioblastoma. Journal of Clinical Oncology. 2025;43. Available from: https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e1463","DOI":"10.1200\/JCO.2025.43.16_suppl.e1463"},{"key":"1947_CR38","doi-asserted-by":"crossref","unstructured":"Gatto L, Nunno VD, Tosoni A, Bartolini S, Ranieri L, Franceschi E. DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open. Cancers. 2023;15(12):3251\u20131. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37370860\/","DOI":"10.3390\/cancers15123251"},{"key":"1947_CR39","unstructured":"Can Immunotherapy Succeed in Glioblastoma?. National Cancer Institute. Cancer.gov. 2018. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/immunotherapy-glioblastoma. Accessed 6 Mar 2025."},{"key":"1947_CR40","doi-asserted-by":"crossref","unstructured":"Ahuja S, Zaheer S. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives. Korean Journal of Clinical Oncology. 2024;20(2):51\u201373. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11717579\/","DOI":"10.14216\/kjco.24009"},{"key":"1947_CR41","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cellular and Molecular Immunology. 2024; Available from: https:\/\/www.nature.com\/articles\/s41423-024-01226-x#Sec18"},{"key":"1947_CR42","doi-asserted-by":"publisher","unstructured":"Ashanti Concepci\u00f3n Uscanga-Palomeque, Ana Karina Ch\u00e1vez-Escamilla, Cynthia Aracely Alvizo-B\u00e1ez, Saavedra-Alonso S, Luis Daniel Terrazas-Armend\u00e1riz, Tamez-Guerra RS et al. CAR-T Cell Therapy: From the Shop to Cancer Therapy. International Journal of Molecular Sciences. 2023;24(21):15688\u20138. https:\/\/doi.org\/10.3390\/ijms242115688","DOI":"10.3390\/ijms242115688"},{"key":"1947_CR43","unstructured":"National Cancer Institute. CAR T cells: Engineering immune cells to treat cancer. National Cancer Institute. Cancer.gov. 2022. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells"},{"key":"1947_CR44","doi-asserted-by":"publisher","unstructured":"Gao Y, Yang L, Li Z, Peng X, Li H. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends. Biomarker Research. 2024 Aug 31 [cited 2024 Sep 28];12(1). Available from: https:\/\/biomarkerres.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40364-024-00644-3","DOI":"10.1186\/s40364-024-00644-3"},{"key":"1947_CR45","doi-asserted-by":"publisher","unstructured":"Frederico SC, Darling C, Bielanin JP, Dubinsky AC, Zhang X, Hadjipanayis CG et al. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. Frontiers in Immunology. 2023;14. Available from: https:\/\/doi.org\/10.3389\/fimmu.2023.1057567","DOI":"10.3389\/fimmu.2023.1057567"},{"key":"1947_CR46","unstructured":"National Cancer Institute. Immune Checkpoint Inhibitors, National Cancer Institute. 2022. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/checkpoint-inhibitors"},{"key":"1947_CR47","unstructured":"Alwithenani A, Hengswat P, Chiocca EA. Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation. Molecular Therapy. 2025 Mar [cited 2025 May 2]; Available from: https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/abstract\/S1525-0016(25)00209-6"},{"key":"1947_CR48","doi-asserted-by":"publisher","unstructured":"Frederico SC, Darling C, Bielanin JP, Dubinsky AC, Zhang X, Hadjipanayis CG, et al. Neoadjuvant immune checkpoint Inhibition in the management of glioblastoma: exploring a new frontier. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1057567","DOI":"10.3389\/fimmu.2023.1057567"},{"key":"1947_CR49","doi-asserted-by":"crossref","unstructured":"Kothari M, Wanjari A, Acharya S, Karwa V, Chavhan R, Kumar S et al. A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach. Cureus. 2024;16(6). Available from: https:\/\/www.cureus.com\/articles\/257020-a-comprehensive-review-of-monoclonal-antibodies-in-modern-medicine-tracing-the-evolution-of-a-revolutionary-therapeutic-approach?score_article=true#","DOI":"10.7759\/cureus.61983"},{"key":"1947_CR50","doi-asserted-by":"crossref","unstructured":"Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights: Oncol. 2013;7:CMO.S8503.","DOI":"10.4137\/CMO.S8503"},{"issue":"14","key":"1947_CR51","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.3390\/polym14142963","volume":"14","author":"C Caraway","year":"2022","unstructured":"Caraway C, Gaitsch H, Wicks EE, Kalluri AL, Navya Kunadi, Tyler B. Polymeric nanoparticles in brain cancer therapy: A review of current approaches. Polymers. 2022;14(14):2963\u20133. https:\/\/doi.org\/10.3390\/polym14142963","journal-title":"Polymers"},{"key":"1947_CR52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, Lei H, Wang J, Xie X, Cheng B, Li Q, Zhang H, Di C. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974. https:\/\/doi.org\/10.1038\/s41419-022-05408-1","journal-title":"Cell Death Dis"},{"key":"1947_CR53","doi-asserted-by":"publisher","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G et al. Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals. Journal of Hematology & Oncology. 2025;18(1). Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13045-025-01704-3","DOI":"10.1186\/s13045-025-01704-3"},{"key":"1947_CR54","doi-asserted-by":"publisher","unstructured":"Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y et al. A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Molecular cancer. 2024;23(1). Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12943-024-01963-7","DOI":"10.1186\/s12943-024-01963-7"},{"key":"1947_CR55","doi-asserted-by":"publisher","unstructured":"Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, et al. Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1254532","DOI":"10.3389\/fimmu.2023.1254532"},{"issue":"5","key":"1947_CR56","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonz\u00e1lez-Mart\u00edn A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab Vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5","journal-title":"Lancet Oncol"},{"key":"1947_CR57","doi-asserted-by":"publisher","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1). https:\/\/doi.org\/10.1056\/NEJMoa2203690","DOI":"10.1056\/NEJMoa2203690"},{"key":"1947_CR58","unstructured":"Trastuzumab deruxtecan (Enhertu.). www.cancerresearchuk.org. [cited 2024 Apr 24]. Available from: https:\/\/www.cancerresearchuk.org"},{"issue":"4","key":"1947_CR59","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the Recombinant humanized anti-HER2 monoclonal antibody\u2013MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913\u201325. https:\/\/doi.org\/10.1007\/s10120-021-01168-7","journal-title":"Gastric Cancer"},{"key":"1947_CR60","doi-asserted-by":"publisher","first-page":"117657","DOI":"10.1016\/j.bmc.2024.117657","volume":"102","author":"D Li","year":"2024","unstructured":"Li D, Sun X, Li Y, Shang C, Dong Y, Zhao R, et al. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy. Bioorg Med Chem. 2024;102:117657\u20137. https:\/\/doi.org\/10.1016\/j.bmc.2024.117657","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"1947_CR61","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","volume":"23","author":"BM Marin","year":"2021","unstructured":"Marin BM, Porath KA, Jain S, Kim M, Conage-Pough JE, Oh JH, et al. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neurooncology. 2021;23(12):2042\u201353. https:\/\/doi.org\/10.1093\/neuonc\/noab133","journal-title":"Neurooncology"},{"key":"1947_CR62","doi-asserted-by":"publisher","unstructured":"Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab Mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neurooncology. 2022;25(2). https:\/\/doi.org\/10.1093\/neuonc\/noac173","DOI":"10.1093\/neuonc\/noac173"},{"key":"1947_CR63","doi-asserted-by":"crossref","unstructured":"Cheng L, Chen L, Shi Y, Gu W, Ding W, Zheng X et al. Efficacy and safety of bispecific antibodies vs. immune checkpoint Blockade combination therapy in cancer: a real-world comparison. Mol Cancer. 2024;23(1).","DOI":"10.1186\/s12943-024-01956-6"},{"key":"1947_CR64","doi-asserted-by":"crossref","unstructured":"Park DH, Bhojnagarwala PS, Liaw K, Devivasha Bordoloi, Tursi NJ, Zhao S et al. Novel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. Journal for ImmunoTherapy of Cancer. 2024 Nov 1 [cited 2024 Dec 4];12(12):e009604\u20134. Available from: https:\/\/jitc.bmj.com\/content\/12\/12\/e009604","DOI":"10.1136\/jitc-2024-009604"},{"key":"1947_CR65","doi-asserted-by":"crossref","unstructured":"Alsajjan R, Mason WP. Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update. Current Oncology. 2023;30(9):8501\u201349. Available from: https:\/\/www.mdpi.com\/1718-7729\/30\/9\/619","DOI":"10.3390\/curroncol30090619"},{"key":"1947_CR66","doi-asserted-by":"crossref","unstructured":"Siva S, Filipczak N, Li X, Md. Abdus Subhan, Parveen F, Jana\u00edna A, Ataide et al. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers. 2023;15(7):2116\u20136. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10093719\/","DOI":"10.3390\/cancers15072116"},{"key":"1947_CR67","doi-asserted-by":"publisher","unstructured":"Hersh AM, Jallo GI, Shimony N. Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics. Frontiers in Oncology. 2022;12. Available from: https:\/\/doi.org\/10.3389\/fonc.2022.982089","DOI":"10.3389\/fonc.2022.982089"},{"key":"1947_CR68","unstructured":"Recovering from brain. tumour surgery| Brain and spinal cord tumours| Cancer Research UK. www.cancerresearchuk.org.2023. Available from: https:\/\/www.cancerresearchuk.org. Accessed 11 Jul 2025."},{"key":"1947_CR69","doi-asserted-by":"crossref","unstructured":"Palmisciano P, Haider AS, Balasubramanian K, Dadario NB, Robertson FC, Silverstein JW et al. Supplementary Motor Area Syndrome After Brain Tumor Surgery: A Systematic Review. World Neurosurgery. 2022 Sep 1 [cited 2022 Dec 3];165:160\u2013171.e2. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35752423\/","DOI":"10.1016\/j.wneu.2022.06.080"},{"key":"1947_CR70","unstructured":"Side effects of surgery. Cancer Council NSW. 2024. Available from: https:\/\/www.cancercouncil.com.au\/brain-cancer\/treatment\/surgery\/side-effects-of-surgery\/. Accessed 5 Mar 2025."},{"key":"1947_CR71","doi-asserted-by":"crossref","unstructured":"Palmisciano P, Haider AS, Balasubramanian K, Dadario NB, Robertson FC, Silverstein JW et al. Supplementary Motor Area Syndrome After Brain Tumor Surgery: A Systematic Review. World Neurosurgery. 2022;165:160\u2013171.e2. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35752423\/","DOI":"10.1016\/j.wneu.2022.06.080"},{"key":"1947_CR72","unstructured":"Cancer Research UK. Side effects of radiotherapy| Brain and spinal cord tumours| Cancer Research UK. Cancerresearchuk.org. 2019. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/brain-tumours\/treatment\/radiotherapy\/side-effects. Accessed 12 Jul 2025."},{"issue":"6","key":"1947_CR73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000354227","volume":"50","author":"JP Warrington","year":"2013","unstructured":"Warrington JP, Ashpole NM, Csiszar A, Lee YR, Ungvari Z, Sonntag WE. Whole brain Radiation-Induced vascular cognitive impairment: mechanisms and implications. J Vasc Res. 2013;50(6):445\u201357. https:\/\/doi.org\/10.1159\/000354227","journal-title":"J Vasc Res"},{"issue":"11","key":"1947_CR74","doi-asserted-by":"publisher","first-page":"101760","DOI":"10.1016\/j.xcrm.2024.101760","volume":"5","author":"WA Banks","year":"2024","unstructured":"Banks WA, Rhea EM, Reed MJ, Erickson MA. The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications. Cell Rep Med. 2024;5(11):101760\u20130. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101760","journal-title":"Cell Rep Med"},{"issue":"1","key":"1947_CR75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","volume":"2","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRX. 2005;2(1):86\u201398. https:\/\/doi.org\/10.1602\/neurorx.2.1.86","journal-title":"NeuroRX"},{"key":"1947_CR76","doi-asserted-by":"crossref","unstructured":"Iturrioz-Rodr\u00edguez N, Sampron N, Matheu A. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics. 2023 [cited 2023 Oct 30];13(9):2734\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37284445\/","DOI":"10.7150\/thno.82005"},{"issue":"2","key":"1947_CR77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/cns-2015-0010","volume":"5","author":"J Yazmin Odia, Sul","year":"2016","unstructured":"Yazmin Odia, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, et al. A phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol. 2016;5(2):59\u201367. https:\/\/doi.org\/10.2217\/cns-2015-0010","journal-title":"CNS Oncol"},{"issue":"6","key":"1947_CR78","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","volume":"127","author":"KJ Habashy","year":"2022","unstructured":"Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. 2022;127(6):976\u201387. https:\/\/doi.org\/10.1038\/s41416-022-01864-w","journal-title":"Br J Cancer"},{"key":"1947_CR79","doi-asserted-by":"crossref","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology. 2022;25(1):123\u201334. Available from: https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/1\/123\/6568419","DOI":"10.1093\/neuonc\/noac099"},{"issue":"11","key":"1947_CR80","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase III trial of chemoradiotherapy with Temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935\u201349. https:\/\/doi.org\/10.1093\/neuonc\/noac116","journal-title":"Neuro Oncol"},{"issue":"4","key":"1947_CR81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/antib12040074","volume":"12","author":"J Rishab Ramapriyan, Sun","year":"2023","unstructured":"Rishab Ramapriyan, Sun J, Curry A, Richardson LG, Ramesh T, Gaffey MA, et al. The role of Antibody-Based therapies in Neuro-Oncology. Antibodies. 2023;12(4):74\u20134. https:\/\/doi.org\/10.3390\/antib12040074","journal-title":"Antibodies"},{"issue":"6","key":"1947_CR82","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/ph18060795","volume":"18","author":"A Bruna-Mej\u00edas","year":"2025","unstructured":"Bruna-Mej\u00edas A, Silva-Bravo V, Moyano Valarezo L, Delgado-Retamal MF, Nazar-Izquierdo D, Aguilar-Aguirre I, et al. The adverse effects and use of bevacizumab in patients with glioblastoma: A systematic review and Meta-Analysis. Pharmaceuticals. 2025;18(6):795. https:\/\/doi.org\/10.3390\/ph18060795","journal-title":"Pharmaceuticals"},{"key":"1947_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4137\/CMO.S7232","volume":"5","author":"MC Chamberlain","year":"2011","unstructured":"Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5:117\u201329. https:\/\/doi.org\/10.4137\/CMO.S7232","journal-title":"Clin Med Insights Oncol"},{"key":"1947_CR84","doi-asserted-by":"crossref","unstructured":"Tsitokana ME, Lafon PA, Laurent Pr\u00e9zeau, Pin J, Philippe Rondard. Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far? International Journal of Molecular Sciences. 2023 Jan 30 [cited 2023 Nov 10];24(3):2632\u20132. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9916958\/","DOI":"10.3390\/ijms24032632"},{"key":"1947_CR85","doi-asserted-by":"crossref","unstructured":"Villase\u00f1or R, Ozmen L, Messaddeq N, Gr\u00fcninger F, Loetscher H, Keller A et al. Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier. Scientific Reports. 2016 May 6 [cited 2025 Jul 12];6(1). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4858719\/","DOI":"10.1038\/srep25658"},{"key":"1947_CR86","doi-asserted-by":"crossref","unstructured":"Iturrioz-Rodr\u00edguez N, Sampron N, Matheu A. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics. 2023;13(9):2734\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37284445\/","DOI":"10.7150\/thno.82005"},{"issue":"1","key":"1947_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Therapy. 2023;8(1):1\u201327. https:\/\/doi.org\/10.1038\/s41392-023-01481-w","journal-title":"Signal Transduct Target Therapy"},{"key":"1947_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/869269","volume":"2014","author":"RK Upadhyay","year":"2014","unstructured":"Upadhyay RK, Drug Delivery Systems CNS, Protection, the Blood Brain Barrier. Biomed Res Int. 2014;2014:1\u201337. https:\/\/doi.org\/10.1155\/2014\/869269","journal-title":"Biomed Res Int"},{"key":"1947_CR89","doi-asserted-by":"publisher","unstructured":"Kadry H, Noorani B, Cucullo L. A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1). https:\/\/doi.org\/10.1186\/s12987-020-00230-3","DOI":"10.1186\/s12987-020-00230-3"},{"issue":"10","key":"1947_CR90","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.7150\/thno.69682","volume":"12","author":"DH Upton","year":"2022","unstructured":"Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics. 2022;12(10):4734\u201352. https:\/\/doi.org\/10.7150\/thno.69682","journal-title":"Theranostics"},{"issue":"5","key":"1947_CR91","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3171\/2016.9.PEDS16152","volume":"19","author":"ACP Sewing","year":"2017","unstructured":"Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, et al. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic Pontine glioma and thalamic high-grade glioma. J Neurosurgery: Pediatr. 2017;19(5):518\u201330. https:\/\/doi.org\/10.3171\/2016.9.PEDS16152","journal-title":"J Neurosurgery: Pediatr"},{"key":"1947_CR92","doi-asserted-by":"publisher","unstructured":"Zvi Lidar, Mardor Y, Jonas T, Pfeffer R, Meir Faibel, Nass D et al. Convection-enhanced delivery of Paclitaxel for the treatment of recurrent malignant glioma: a phase I\/II clinical study. 2004;100(3):472\u20139. https:\/\/doi.org\/10.3171\/jns.2004.100.3.0472","DOI":"10.3171\/jns.2004.100.3.0472"},{"key":"1947_CR93","doi-asserted-by":"crossref","unstructured":"Durham PG, Butnariu A, Rizk Alghorazi G, Pinton, Krishna V, Dayton PA. Current clinical investigations of focused ultrasound blood-brain barrier disruption: A review. Neurotherapeutics. 2024 Apr 1 [cited 2024 Aug 23];21(3):e00352\u20132. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11044032\/","DOI":"10.1016\/j.neurot.2024.e00352"},{"key":"1947_CR94","doi-asserted-by":"publisher","unstructured":"Pouliopoulos AN, Kwon N, Jensen G, Anna Maria Meaney, Niimi Y, Burgess M et al. Safety evaluation of a clinical focused ultrasound system for neuronavigation guided blood-brain barrier opening in non-human primates. 2021;11(1). https:\/\/doi.org\/10.1038\/s41598-021-94188-3","DOI":"10.1038\/s41598-021-94188-3"},{"issue":"7","key":"1947_CR95","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","volume":"12","author":"I Khan","year":"2017","unstructured":"Khan I, Saeed K, Khan I, Nanoparticles. Properties, applications and toxicities. Arab J Chem. 2017;12(7):908\u201331. https:\/\/doi.org\/10.1016\/j.arabjc.2017.05.011","journal-title":"Arab J Chem"},{"key":"1947_CR96","doi-asserted-by":"publisher","unstructured":"Ahamed J, Jaswanth BH, Gowda, Almalki WH, Gupta N, Amirhossein, Sahebkar, Prashant Kesharwani. Recent advances in nanoparticle-based approaches for the treatment of brain tumors: Opportunities and challenges. European Polymer Journal. 2023;193:112111\u20131. Available from: https:\/\/doi.org\/10.1016\/j.eurpolymj.2023.112111","DOI":"10.1016\/j.eurpolymj.2023.112111"},{"key":"1947_CR97","doi-asserted-by":"crossref","unstructured":"Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles\u2019 Physicochemical Properties on Responses in Biological Systems. Polymers. 2023;15(7):1596. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10096782\/","DOI":"10.3390\/polym15071596"},{"key":"1947_CR98","doi-asserted-by":"publisher","unstructured":"Walter FR, Santa-Maria AR, M\u00e9sz\u00e1ros M, Veszelka S, D\u00e9r A, Deli MA. Surface charge, glycocalyx, and BBB function. Tissue Barriers. 2021;9(3). https:\/\/doi.org\/10.1080\/21688370.2021.1904773","DOI":"10.1080\/21688370.2021.1904773"},{"key":"1947_CR99","doi-asserted-by":"crossref","unstructured":"Ayub A, Wettig S. An Overview of Nanotechnologies for Drug Delivery to the Brain. Pharmaceutics. 2022;14(2):224. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35213957\/","DOI":"10.3390\/pharmaceutics14020224"},{"key":"1947_CR100","doi-asserted-by":"publisher","unstructured":"Moreira R, N\u00f3brega C, de Almeida LP, Mendon\u00e7a L. Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands. J Nanobiotechnol. 2024;22(1). https:\/\/doi.org\/10.1186\/s12951-024-02511-7","DOI":"10.1186\/s12951-024-02511-7"},{"key":"1947_CR101","doi-asserted-by":"crossref","unstructured":"Ohtsuki S. Insulin receptor at the BBB: Transport and signaling. Vitamins and hormones. 2024;126:113\u201324. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39029970\/","DOI":"10.1016\/bs.vh.2024.05.001"},{"issue":"10","key":"1947_CR102","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","volume":"14","author":"MS Thomsen","year":"2022","unstructured":"Thomsen MS, Johnsen KB, Kucharz K, Lauritzen M, Moos T. Blood\u2013Brain barrier transport of transferrin Receptor-Targeted nanoparticles. Pharmaceutics. 2022;14(10):2237. https:\/\/doi.org\/10.3390\/pharmaceutics14102237","journal-title":"Pharmaceutics"},{"key":"1947_CR103","doi-asserted-by":"publisher","unstructured":"Beach MA, Umeka Nayanathara, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9). https:\/\/doi.org\/10.1021\/acs.chemrev.3c00705","DOI":"10.1021\/acs.chemrev.3c00705"},{"issue":"10","key":"1947_CR104","doi-asserted-by":"publisher","first-page":"2003937","DOI":"10.1002\/advs.202003937","volume":"8","author":"W Zhang","year":"2021","unstructured":"Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymer nanoparticles for Blood\u2013Brain barrier Transfer\u2014Strategies and challenges. Adv Sci. 2021;8(10):2003937. https:\/\/doi.org\/10.1002\/advs.202003937","journal-title":"Adv Sci"},{"key":"1947_CR105","doi-asserted-by":"publisher","unstructured":"Neganova ME, Aleksandrova YR, Sukocheva OA, Klochkov SG. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Sem Cancer Biol. 2022 Jun;30. https:\/\/doi.org\/10.1016\/j.semcancer.2022.06.011","DOI":"10.1016\/j.semcancer.2022.06.011"},{"key":"1947_CR106","doi-asserted-by":"publisher","unstructured":"Xiao X, Teng F, Shi C, Chen J, Wu S, Wang B, et al. Polymer nanoparticles\u2014Promising carriers for cancer therapy. Front Bioeng Biotechnol. 2022;10. https:\/\/doi.org\/10.3389\/fbioe.2022.1024143","DOI":"10.3389\/fbioe.2022.1024143"},{"issue":"4","key":"1947_CR107","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/10937404.2024.2326679","volume":"27","author":"V Alves","year":"2024","unstructured":"Alves V, Helber Alves Negreiros, Barbosa G, Farias K, Alves P, Alves A, et al. Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review. J Toxicol Environ Health Part B. 2024;27(4):131\u201352. https:\/\/doi.org\/10.1080\/10937404.2024.2326679","journal-title":"J Toxicol Environ Health Part B"},{"key":"1947_CR108","doi-asserted-by":"publisher","unstructured":"Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A. Sustained drug release from smart nanoparticles in cancer therapy: A comprehensive review. 2022;13(10):1623\u20133. https:\/\/doi.org\/10.3390\/mi13101623https:\/\/doi.org\/10.1186\/s13045-024-01535-8","DOI":"10.3390\/mi13101623"},{"key":"1947_CR109","doi-asserted-by":"crossref","unstructured":"Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioactive Materials. 2021;6(7):1973\u201387. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2452199X20303352","DOI":"10.1016\/j.bioactmat.2020.12.010"},{"key":"1947_CR110","doi-asserted-by":"crossref","unstructured":"Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep. 2016;6(1).","DOI":"10.1038\/srep26269"},{"key":"1947_CR111","doi-asserted-by":"publisher","unstructured":"Sharma AK, Gupta L, Sahu H, Qayum A, Singh SK, Nakhate KT, et al. Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced Anti-Cancer potential and improved in vivo brain pharmacokinetics of Temozolomide. Pharm Res. 2018;35(1). https:\/\/doi.org\/10.1007\/s11095-017-2324-y","DOI":"10.1007\/s11095-017-2324-y"},{"key":"1947_CR112","doi-asserted-by":"crossref","unstructured":"Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers. 2011;3(3):1377\u201397. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3347861\/","DOI":"10.3390\/polym3031377"},{"key":"1947_CR113","doi-asserted-by":"publisher","first-page":"118733","DOI":"10.1016\/j.ijpharm.2019.118733","volume":"572","author":"O Maksimenko","year":"2019","unstructured":"Maksimenko O, Malinovskaya J, Shipulo E, Osipova N, Razzhivina V, Arantseva D, et al. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: towards the pharmaceutical development. Int J Pharm. 2019;572:118733. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118733","journal-title":"Int J Pharm"},{"issue":"14","key":"1947_CR114","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.3390\/polym14142963","volume":"14","author":"C Caraway","year":"2022","unstructured":"Caraway C, Gaitsch H, Wicks EE, Kalluri AL, Navya, Kunadi. Tyler B. polymer nanoparticles in brain cancer therapy: A review of current approaches. Polymers. 2022;14(14):2963\u20133. https:\/\/doi.org\/10.3390\/polym14142963","journal-title":"Polymers"},{"issue":"6","key":"1947_CR115","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/bm5003009","volume":"15","author":"Y Zhong","year":"2014","unstructured":"Zhong Y, Meng F, Deng C, Zhong Z. Ligand-Directed active Tumor-Targeting polymer nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955\u201369. https:\/\/doi.org\/10.1021\/bm5003009","journal-title":"Biomacromolecules"},{"key":"1947_CR116","doi-asserted-by":"crossref","unstructured":"Fana M, Gallien J, Srinageshwar B, Dunbar GL, Rossignol J. PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review. International Journal of Nanomedicine. 2020;15:2789\u2013808. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7185330\/","DOI":"10.2147\/IJN.S243155"},{"key":"1947_CR117","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.carpta.2024.100427","volume":"7","author":"M Wiranowska","year":"2024","unstructured":"Wiranowska M. Advances in the use of Chitosan and chlorotoxin- functionalized Chitosan polymers in drug delivery and detection of glioma\u2013 A review. Carbohydr Polym Technol Appl. 2024;7:100427. https:\/\/doi.org\/10.1016\/j.carpta.2024.100427","journal-title":"Carbohydr Polym Technol Appl"},{"key":"1947_CR118","doi-asserted-by":"publisher","unstructured":"Raucher D, Dragojevic S, Ryu J. Macromolecular drug carriers for targeted glioblastoma therapy: preclinical studies, challenges, and future perspectives. Front Oncol. 2018;8. https:\/\/doi.org\/10.3389\/fonc.2018.00624","DOI":"10.3389\/fonc.2018.00624"},{"issue":"17","key":"1947_CR119","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.2174\/0929867311320170006","volume":"20","author":"G Tosi","year":"2013","unstructured":"Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, et al. Potential use of polymer nanoparticles for drug delivery across the BBB. Curr Med Chem. 2013;20(17):2212\u201325. https:\/\/doi.org\/10.2174\/0929867311320170006","journal-title":"Curr Med Chem"},{"key":"1947_CR120","doi-asserted-by":"publisher","unstructured":"Habib Baghirov. Mechanisms of receptor-mediated transcytosis at the blood-brain barrier. Journal of Controlled Release. 2025;381:113595\u20135. Available from: https:\/\/doi.org\/10.1016\/j.jconrel.2025.113595","DOI":"10.1016\/j.jconrel.2025.113595"},{"key":"1947_CR121","doi-asserted-by":"publisher","unstructured":"Tu J, Ding Y, Zhou L, Shi D, Sun L, Webster TJ, et al. Noninvasive nanoparticle strategies for brain tumor targeting. Nanomed Nanotechnol Biol Med. 2017;13(8). https:\/\/doi.org\/10.1016\/j.nano.2017.07.009","DOI":"10.1016\/j.nano.2017.07.009"},{"key":"1947_CR122","doi-asserted-by":"publisher","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB. Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Frontiers in drug delivery. 2024;4. Available from: https:\/\/doi.org\/10.3389\/fddev.2024.1360302","DOI":"10.3389\/fddev.2024.1360302"},{"key":"1947_CR123","doi-asserted-by":"crossref","unstructured":"Top\u00e7u BT, Bozda\u011f Pehlivan S, Akda\u011f Y, Mut M, \u00d6ner L. Antibody Conjugated Nano-Enabled Drug Delivery Systems Against Brain Tumors. Journal of Pharmaceutical Sciences. 2024;113(6):1455\u201369. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38555997\/","DOI":"10.1016\/j.xphs.2024.03.017"},{"issue":"4","key":"1947_CR124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/antib11040078","volume":"11","author":"T Tashima","year":"2022","unstructured":"Tashima T. Delivery of drugs into cancer cells using Antibody\u2013Drug conjugates based on Receptor-Mediated endocytosis and the enhanced permeability and retention effect. Antibodies. 2022;11(4):78.","journal-title":"Antibodies"},{"key":"1947_CR125","doi-asserted-by":"crossref","unstructured":"Yang X, Pan Z, Choudhury MR, Yuan Z, Abiodun Anifowose, Yu B et al. Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery. Medicinal Research Reviews. 2020;40(6):2682\u2013713. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7817242\/","DOI":"10.1002\/med.21720"},{"key":"1947_CR126","doi-asserted-by":"publisher","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","volume":"592","author":"EdaS Santos","year":"2021","unstructured":"Santos EdaS, Nogueira KAB, Fernandes LCC, Martins JRP, Reis AVF, Neto J, de BV, et al. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm. 2021;592:120082. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120082","journal-title":"Int J Pharm"},{"issue":"3","key":"1947_CR127","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/imt.11.5","volume":"3","author":"F Fay","year":"2011","unstructured":"Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy. 2011;3(3):381\u201394. https:\/\/doi.org\/10.2217\/imt.11.5","journal-title":"Immunotherapy"},{"key":"1947_CR128","doi-asserted-by":"publisher","unstructured":"Tian X, Nyberg S, Sharp PM, Madsen J, Nooshin Daneshpour, Armes SP, et al. LRP-1-mediated intracellular antibody delivery to the central nervous system. Sci Rep. 2015;5(1). https:\/\/doi.org\/10.1038\/srep11990","DOI":"10.1038\/srep11990"},{"key":"1947_CR129","doi-asserted-by":"publisher","unstructured":"Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025;32(1). https:\/\/doi.org\/10.1186\/s12929-025-01119-9","DOI":"10.1186\/s12929-025-01119-9"},{"key":"1947_CR130","doi-asserted-by":"crossref","unstructured":"Esparza TJ, Su S, Francescutti CM, Rodionova E, Kim JH, Brody DL. Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody. Fluids and Barriers of the CNS. 2023;20(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37620930\/","DOI":"10.1186\/s12987-023-00462-z"},{"issue":"6","key":"1947_CR131","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/brainsci15060585","volume":"15","author":"F Ruchika","year":"2025","unstructured":"Ruchika F, Suvarnapathaki S, Serrano-Farias A, Bettegowda C, Rincon-Torroella J. GLUT1 as a potential therapeutic target in glioblastoma. Brain Sci. 2025;15(6):585. https:\/\/doi.org\/10.3390\/brainsci15060585","journal-title":"Brain Sci"},{"issue":"32","key":"1947_CR132","doi-asserted-by":"publisher","first-page":"23520","DOI":"10.1039\/d4ra04069d","volume":"14","author":"MM Agwa","year":"2024","unstructured":"Agwa MM, Marzouk RE, Sabra SA. Advances in active targeting of ligand-directed polymeric nanomicelles via exploiting overexpressed cellular receptors for precise nanomedicine. RSC Adv. 2024;14(32):23520\u201342. https:\/\/doi.org\/10.1039\/d4ra04069d","journal-title":"RSC Adv"},{"issue":"8","key":"1947_CR133","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/pharmaceutics13081193","volume":"13","author":"DJ Lundy","year":"2021","unstructured":"Lundy DJ, Nguy\u1ec5n H, Hsieh PCH. Emerging Nano-Carrier strategies for brain tumor drug delivery and considerations for clinical translation. Pharmaceutics. 2021;13(8):1193. https:\/\/doi.org\/10.3390\/pharmaceutics13081193","journal-title":"Pharmaceutics"},{"issue":"4","key":"1947_CR134","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0168-0102(99)00056-5","volume":"34","author":"RJ Boado","year":"1999","unstructured":"Boado RJ, Wu D, Windisch M. In vivo upregulation of the blood\u2013brain barrier GLUT1 glucose transporter by brain-derived peptides. Neurosci Res. 1999;34(4):217\u201324. https:\/\/doi.org\/10.1016\/s0168-0102(99)00056-5","journal-title":"Neurosci Res"},{"issue":"10","key":"1947_CR135","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3109\/1061186X.2013.840639","volume":"21","author":"AH Abouzeid","year":"2013","unstructured":"Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with Curcumin and doxorubicin. J Drug Target. 2013;21(10):994\u20131000.","journal-title":"J Drug Target"},{"key":"1947_CR136","doi-asserted-by":"crossref","unstructured":"Zhu Y, Verkhratsky A, Chen H, Yi C. Understanding glucose metabolism and insulin action at the blood\u2013brain barrier: Implications for brain health and neurodegenerative diseases. Acta Physiologica. 2025 Jan 16 [cited 2025 Mar 26];241(2). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11737474\/","DOI":"10.1111\/apha.14283"},{"key":"1947_CR137","doi-asserted-by":"publisher","unstructured":"Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer\u2019s disease and diabetes. The Journal of Pathology. 2011 May 19 [cited 2019 Aug 8];225(1):54\u201362. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/path.2912","DOI":"10.1002\/path.2912"},{"issue":"20","key":"1947_CR138","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1016\/j.biomaterials.2013.03.013","volume":"34","author":"YC Kuo","year":"2013","unstructured":"Kuo YC, Ko HF. Targeting delivery of saquinavir to the brain using 83\u2013\u200914 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials. 2013;34(20):4818\u201330. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.03.013","journal-title":"Biomaterials"},{"key":"1947_CR139","doi-asserted-by":"publisher","unstructured":"Zhan M, Qiu J, Fan Y, Chen L, Guo Y, Wang Z, et al. Phosphorous dendron micelles as a nanomedicine platform for cooperative tumor chemoimmunotherapy via synergistic modulation of immune cells. Adv Mater. 2022;35(3). https:\/\/doi.org\/10.1002\/adma.202208277","DOI":"10.1002\/adma.202208277"},{"key":"1947_CR140","doi-asserted-by":"publisher","first-page":"121860","DOI":"10.1016\/j.ijpharm.2022.121860","volume":"622","author":"H Yuan","year":"2022","unstructured":"Yuan H, Xue Y, Guo C, Song J, Zhang Y, Yin T, et al. Thermodynamic stability of cisplatin-loaded polymeric micelles and the phenotypic switching of the tumor-associated macrophages induced by combination of cisplatin-loaded micelles and Anti-PD-L1 antibody. Int J Pharm. 2022;622:121860. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121860","journal-title":"Int J Pharm"},{"issue":"21","key":"1947_CR141","doi-asserted-by":"publisher","first-page":"9816","DOI":"10.1039\/D0NR08191D","volume":"13","author":"J Maximilian Br\u00fcckner, Simon","year":"2021","unstructured":"Maximilian Br\u00fcckner, Simon J, Landfester K, Volker Mail\u00e4nder. The conjugation strategy affects antibody orientation and targeting properties of nanocarriers. Nanoscale. 2021;13(21):9816\u201324. https:\/\/doi.org\/10.1039\/D0NR08191D","journal-title":"Nanoscale"},{"key":"1947_CR142","doi-asserted-by":"publisher","unstructured":"Kumari M, Acharya A, Praveen T, Krishnamurthy. Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics. Beilstein Journal of Nanotechnology. 2023 Sep 4 [cited 2023 Dec 17];14:912\u201326. Available from: https:\/\/doi.org\/10.3762\/bjnano.14.75","DOI":"10.3762\/bjnano.14.75"},{"key":"1947_CR143","doi-asserted-by":"publisher","unstructured":"Adhikari A, Chen IA. Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds. Small. 2025 Mar 6. Available from: https:\/\/doi.org\/10.1002\/smll.202409635","DOI":"10.1002\/smll.202409635"},{"key":"1947_CR144","doi-asserted-by":"publisher","unstructured":"Lin X, O\u2019Reilly Beringhs A, Lu X. Applications of Nanoparticle-Antibody conjugates in immunoassays and tumor imaging. AAPS J. 2021;23(2). https:\/\/doi.org\/10.1208\/s12248-021-00561-5","DOI":"10.1208\/s12248-021-00561-5"},{"key":"1947_CR145","unstructured":"Nanopartz Ligands. Comparing Adsorbed and Covalent Ligands. Nanopartz.com. 2025 [cited 2025 May 22]. Available from: https:\/\/www.nanopartz.com\/Technical-Notes\/Comparing-Adsorbed-And-Covalent-Ligands.asp"},{"issue":"9","key":"1947_CR146","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/pharmaceutics12090802","volume":"12","author":"A Juan","year":"2020","unstructured":"Juan A, Cimas FJ, Bravo I, Pandiella A, Oca\u00f1a A, Alonso-Moreno C. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics. 2020;12(9):802. https:\/\/doi.org\/10.3390\/pharmaceutics12090802","journal-title":"Pharmaceutics"},{"key":"1947_CR147","doi-asserted-by":"publisher","unstructured":"Lee NK, Wang CPJ, Lim J, Park W, Kwon HK, Kim SN, et al. Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities. Nano Convergence. 2021;8(1). https:\/\/doi.org\/10.1186\/s40580-021-00274-7","DOI":"10.1186\/s40580-021-00274-7"},{"key":"1947_CR148","doi-asserted-by":"crossref","unstructured":"Hui L, Chen W, Najlah M. The challenges to develop antibody-conjugated nanomedicine products. Nano TransMed. 2023 Dec 1 [cited 2024 Jan 5];2(4):100018. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2790676023000523#:~:text=Antibody%2Dconjugated","DOI":"10.1016\/j.ntm.2023.100018"},{"key":"1947_CR149","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2017.04.016","volume":"255","author":"C Monterrubio","year":"2017","unstructured":"Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, et al. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. J Controlled Release. 2017;255:108\u201319. https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.016","journal-title":"J Controlled Release"},{"key":"1947_CR150","doi-asserted-by":"publisher","unstructured":"Hoover EC, Chowdhury CR, Ruggiero OM, Day ES. Conjugation of Antibodies and siRNA Duplexes to Polymer Nanoparticles via Maleimide\u2013Thiol Chemistry. ACS Omega. 2024;9(48):47637\u201346. Available from: https:\/\/pubs.acs.org\/doi\/https:\/\/doi.org\/10.1021\/acsomega.4c07025","DOI":"10.1021\/acsomega.4c07025"},{"key":"1947_CR151","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","volume":"282","author":"S Luc\u00eda Mart\u00ednez-Jothar, Doulkeridou","year":"2018","unstructured":"Luc\u00eda Mart\u00ednez-Jothar, Doulkeridou S, Schiffelers RM, Javier Sastre Tora\u00f1o, Oliveira S, van Nostrum, et al. Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting. J Controlled Release. 2018;282:101\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.002","journal-title":"J Controlled Release"},{"issue":"9","key":"1947_CR152","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/mabi.201200037","volume":"12","author":"J Yue","year":"2012","unstructured":"Yue J, Liu S, Wang R, Hu X, Xie Z, Huang Y, et al. Fluorescence-Labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the Blood\u2013Brain barrier. Macromol Biosci. 2012;12(9):1209\u201319. https:\/\/doi.org\/10.1002\/mabi.201200037","journal-title":"Macromol Biosci"},{"key":"1947_CR153","doi-asserted-by":"publisher","unstructured":"Luu T, Gristwood K, Knight JC, J\u00f6rg M. Click chemistry: reaction rates and their suitability for biomedical applications. Bioconjug Chem. 2024;35(6). https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00084","DOI":"10.1021\/acs.bioconjchem.4c00084"},{"key":"1947_CR154","doi-asserted-by":"publisher","first-page":"106982","DOI":"10.1016\/j.bioorg.2023.106982","volume":"143","author":"M Rostyslav Dudchak, Podolak","year":"2024","unstructured":"Rostyslav Dudchak, Podolak M, Holota S, Szewczyk-Roszczenko O, Piotr Roszczenko, Bielawska A, et al. Click chemistry in the synthesis of antibody-drug conjugates. Bioorg Chem. 2024;143:106982\u20132. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106982","journal-title":"Bioorg Chem"},{"issue":"1","key":"1947_CR155","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/acschembio.4c00608","volume":"20","author":"I Oprea","year":"2024","unstructured":"Oprea I, Smith TK. Click chemistry methodology: the novel paintbrush of drug design. ACS Chem Biol. 2024;20(1):19\u201332. https:\/\/doi.org\/10.1021\/acschembio.4c00608","journal-title":"ACS Chem Biol"},{"issue":"6","key":"1947_CR156","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/vaccines9060563","volume":"9","author":"L Lu","year":"2021","unstructured":"Lu L, Duong VT, Shalash AO, Skwarczynski M, Toth I. Chemical conjugation strategies for the development of Protein-Based subunit nanovaccines. Vaccines. 2021;9(6):563. https:\/\/doi.org\/10.3390\/vaccines9060563","journal-title":"Vaccines"},{"issue":"4","key":"1947_CR157","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/pharmaceutics15041241","volume":"15","author":"Z Yang","year":"2023","unstructured":"Yang Z, Li H, Zhang W, Zhang M, He J, Yu Z, et al. CD163 monoclonal antibody modified polymer prodrug nanoparticles for targeting Tumor-Associated macrophages (TAMs) to enhance Anti-Tumor effects. Pharmaceutics. 2023;15(4):1241\u20131. https:\/\/doi.org\/10.3390\/pharmaceutics15041241","journal-title":"Pharmaceutics"},{"key":"1947_CR158","doi-asserted-by":"crossref","unstructured":"Soxpollard N, Strauss S, Jungmann R, MacPherson IS. Selection of antibody-binding covalent aptamers. Communications Chemistry. 2024 Aug 8 [cited 2024 Dec 1];7(1). Available from: https:\/\/www.nature.com\/articles\/s42004-024-01255-7","DOI":"10.1038\/s42004-024-01255-7"},{"key":"1947_CR159","doi-asserted-by":"crossref","unstructured":"Balzer AHA, Whitehurst CB. An Analysis of the Biotin\u2013(Strept)avidin System in Immunoassays: Interference and Mitigation Strategies. Current Issues in Molecular Biology. 2023;45(11):8733\u201354. Available from: https:\/\/www.mdpi.com\/1467-3045\/45\/11\/549","DOI":"10.3390\/cimb45110549"},{"key":"1947_CR160","unstructured":"Avidin-Biotin. Jul Interaction - US. www.thermofisher.com. [cited 2020 Oct 14]. Available from: https:\/\/www.thermofisher.com. Accessed 12 2025."},{"key":"1947_CR161","doi-asserted-by":"publisher","unstructured":"Jain A, Cheng K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. Journal of Controlled Release. 2017;245:27\u201340. Available from: https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.016","DOI":"10.1016\/j.jconrel.2016.11.016"},{"key":"1947_CR162","doi-asserted-by":"crossref","unstructured":"Marques AC, Costa PC, Velho S, Amaral MH. Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles. Life. 2024 Apr 1 [cited 2024 May 6];14(4):489. Available from: https:\/\/www.mdpi.com\/2075-1729\/14\/4\/489.","DOI":"10.3390\/life14040489"},{"issue":"11","key":"1947_CR163","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1021\/acs.molpharmaceut.0c00856","volume":"17","author":"A Banstola","year":"2020","unstructured":"Banstola A, Duwa R, Emami F, Jeong JH, Yook S. Enhanced Caspase-Mediated abrogation of autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-co-glycolic acid) nanoparticles in epidermal growth factor receptor overexpressing glioblastoma cells. Mol Pharm. 2020;17(11):4386\u2013400. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00856","journal-title":"Mol Pharm"},{"key":"1947_CR164","unstructured":"LibreTexts. Introduction to NMR. Chemistry LibreTexts. 2019. Available from: https:\/\/chem.libretexts.org\/Bookshelves\/Physical_and_Theoretical_Chemistry_Textbook_Maps\/Supplemen. Accessed 12 Jul 2025."},{"key":"1947_CR165","doi-asserted-by":"crossref","unstructured":"Andrade F, Rafael D, Vilar-Hern\u00e1ndez M, Montero S, Mart\u00ednez-Trucharte F, Seras-Franzoso J et al. Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. Journal of Controlled Release. 2021;331:198\u2013212. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0168365921000316?via%3Dihub","DOI":"10.1016\/j.jconrel.2021.01.022"},{"issue":"8","key":"1947_CR166","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s10856-012-4658-7","volume":"23","author":"H Bao","year":"2012","unstructured":"Bao H, Jin X, Li L, Lv F, Liu T. OX26 modified hyperbranched polyglycerol-conjugated poly(lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J Mater Science: Mater Med. 2012;23(8):1891\u2013901. https:\/\/doi.org\/10.1007\/s10856-012-4658-7","journal-title":"J Mater Science: Mater Med"},{"key":"1947_CR167","doi-asserted-by":"crossref","unstructured":"Xu S, Cui F, Huang D, Zhang D, Zhu A, Sun X et al. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. International Journal of Nanomedicine. 2018 Dec 18 [cited 2021 Jul 6];14:17\u201332. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6302817\/","DOI":"10.2147\/IJN.S175340"},{"issue":"24","key":"1947_CR168","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2217\/nnm-2020-0167","volume":"15","author":"MK Viswanadh","year":"2020","unstructured":"Viswanadh MK, Vikas, Jha A, Reddy Adena SK, Mehata AK, Priya V, et al. Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. Nanomedicine. 2020;15(24):2345\u201367. https:\/\/doi.org\/10.2217\/nnm-2020-0167","journal-title":"Nanomedicine"},{"key":"1947_CR169","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejpb.2016.08.013","volume":"108","author":"C Sarisozen","year":"2016","unstructured":"Sarisozen C, Dhokai S, Tsikudo EG, Luther E, Rachman IM, Torchilin VP. Nanomedicine based Curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: in vitro evaluation on 2D and 3D tumor models. Eur J Pharm Biopharm. 2016;108:54\u201367. https:\/\/doi.org\/10.1016\/j.ejpb.2016.08.013","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1947_CR170","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1006\/abio.1993.1319","volume":"212","author":"WE Werner","year":"1993","unstructured":"Werner WE, Demorest DM, Stevens J, Wiktorowicz JE. Size-Dependent separation of proteins denatured in SDS by capillary electrophoresis using a replaceable Sieving matrix. Anal Biochem. 1993;212(1):253\u20138. https:\/\/doi.org\/10.1006\/abio.1993.1319","journal-title":"Anal Biochem"},{"key":"1947_CR171","unstructured":"Janeway C, Travers P, Walport M, Shlomchik MJ. The Structure of a Typical Antibody Molecule. Nih.gov. Garland Science; 2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK27144\/"},{"key":"1947_CR172","doi-asserted-by":"crossref","unstructured":"Sun T, Li Y, Huang Y, Zhang Z, Yang W, Du Z et al. Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy. Oncotarget. 2016;7(28). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5190011\/","DOI":"10.18632\/oncotarget.9355"},{"key":"1947_CR173","doi-asserted-by":"publisher","first-page":"100134","DOI":"10.1016\/j.medidd.2022.100134","volume":"15","author":"A Sultana","year":"2022","unstructured":"Sultana A, Zare M, Thomas V, Kumar TSS, Ramakrishna S. Nano-based drug delivery systems: conventional drug delivery routes, recent developments and future prospects. Med Drug Discovery. 2022;15:100134.","journal-title":"Med Drug Discovery"},{"issue":"3","key":"1947_CR174","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jconrel.2007.05.032","volume":"122","author":"M Fujita","year":"2007","unstructured":"Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(\u03b2-l-malic acid). J Controlled Release. 2007;122(3):356\u201363. https:\/\/doi.org\/10.1016\/j.jconrel.2007.05.032","journal-title":"J Controlled Release"},{"issue":"5","key":"1947_CR175","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.vaccine.2009.10.153","volume":"28","author":"AL Dominguez","year":"2010","unstructured":"Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu\/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine. 2010;28(5):1383\u201390. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.153","journal-title":"Vaccine"},{"key":"1947_CR176","doi-asserted-by":"crossref","unstructured":"Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. Pharmaceutics. 2022;14(4):883. Available from: https:\/\/www.mdpi.com\/1999-4923\/14\/4\/883","DOI":"10.3390\/pharmaceutics14040883"},{"issue":"4","key":"1947_CR177","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1021\/acs.molpharmaceut.9b01280","volume":"17","author":"Y Liu","year":"2020","unstructured":"Liu Y, Scrivano L, Peterson JD, Fens MHAM, Hern\u00e1ndez IB, Mesquita B, et al. EGFR-Targeted nanobody functionalized polymeric micelles loaded with mTHPC for selective photodynamic therapy. Mol Pharm. 2020;17(4):1276\u201392. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01280","journal-title":"Mol Pharm"},{"issue":"12","key":"1947_CR178","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1021\/acs.molpharmaceut.3c00558","volume":"20","author":"M Lim","year":"2023","unstructured":"Lim M, Fletcher NL, Saunus JM, McCart Reed AE, Chittoory H, Simpson PT, et al. Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis. Mol Pharm. 2023;20(12):6169\u201383. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00558","journal-title":"Mol Pharm"},{"key":"1947_CR179","doi-asserted-by":"crossref","unstructured":"Hamdy NM, Eskander G, Basalious EB. Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques. International Journal of Nanomedicine. 2022 Dec 7 [cited 2023 Mar 24];17:6131\u201355. Available from: https:\/\/www.dovepress.com\/insights-on-the-dynamic-innovative-tumor-targeted-nanoparticles-based--peer-reviewed-fulltext-article-IJN","DOI":"10.2147\/IJN.S386037"},{"key":"1947_CR180","doi-asserted-by":"publisher","unstructured":"Ding H, Inoue S, Ljubimov AV, Patil R, Portilla-Arias J, Hu J et al. Inhibition of brain tumor growth by intravenous poly(\u03b2-l-malic acid) nanobioconjugate with pH-dependent drug release. Proceedings of the National Academy of Sciences. 2010;107(42):18143\u20138. https:\/\/doi.org\/10.1073\/pnas.1003919107","DOI":"10.1073\/pnas.1003919107"},{"issue":"3","key":"1947_CR181","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ejpb.2012.10.017","volume":"83","author":"D Torrecilla","year":"2013","unstructured":"Torrecilla D, Lozano MV, Lallana E, Neissa JI, Novoa-Carballal R, Vidal A, et al. Anti-tumor efficacy of chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized nanocapsules vs. non-functionalized nanocapsules. Eur J Pharm Biopharm. 2013;83(3):330\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2012.10.017","journal-title":"Eur J Pharm Biopharm"},{"key":"1947_CR182","doi-asserted-by":"crossref","unstructured":"Perumal S, Atchudan R, Lee W. A Review of Polymeric Micelles and Their Applications. Polymers. 2022;14(12):2510. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9230755\/#:~:text=Micelles%20are%20prepared%2","DOI":"10.3390\/polym14122510"},{"key":"1947_CR183","unstructured":"Ahmadi M, Siavashy S, Ayyoubzadeh SM, Kecili R, Ghorbani-Bidkorbeh F. Controllable Synthesis of Polymeric Micelles by Microfluidic Platforms for Biomedical Applications: A Systematic Review. Iranian journal of pharmaceutical research: IJPR. 2021 [cited 2023 Feb 20];20(2):229\u201340. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8457734\/"},{"key":"1947_CR184","doi-asserted-by":"crossref","unstructured":"Negu\u021b I, Bogdan Bi\u021b\u0103. Polymeric Micellar Systems\u2014A Special Emphasis on Smart Drug Delivery. Pharmaceutics. 2023;15(3):976\u20136. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10056703\/","DOI":"10.3390\/pharmaceutics15030976"},{"key":"1947_CR185","doi-asserted-by":"crossref","unstructured":"Ghezzi M. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. Journal of Controlled Release. 2021;332:312\u201336. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168365921001061#","DOI":"10.1016\/j.jconrel.2021.02.031"},{"issue":"19\u201320","key":"1947_CR186","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00018-004-4153-5","volume":"61","author":"VP Torchilin","year":"2004","unstructured":"Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci. 2004;61(19\u201320):2549\u201359. https:\/\/doi.org\/10.1007\/s00018-004-4153-5","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"1947_CR187","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.biomaterials.2012.08.072","volume":"34","author":"H Wu","year":"2013","unstructured":"Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG\/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials. 2013;34(4):1213\u201322. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.08.072","journal-title":"Biomaterials"},{"issue":"1","key":"1947_CR188","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acs.biomac.8b01616","volume":"20","author":"R Pola","year":"2018","unstructured":"Pola R, Vlastimil Kr\u00e1l, Filippov SK, Leonid Kaberov, Tom\u00e1\u0161 Etrych, Sieglov\u00e1 I, et al. Polymer cancerostatics targeted by Recombinant antibody fragments to GD2-Positive tumor cells. Biomacromolecules. 2018;20(1):412\u201321. https:\/\/doi.org\/10.1021\/acs.biomac.8b01616","journal-title":"Biomacromolecules"},{"issue":"8","key":"1947_CR189","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1021\/acsnano.0c03386","volume":"14","author":"S Hiroaki Kinoh, Quader","year":"2020","unstructured":"Hiroaki Kinoh, Quader S, Hitoshi S, Liu X, Amit Maity T, Yamasoba, et al. Translational nanomedicine boosts Anti-PD1 therapy to eradicate orthotopic PTEN-Negative glioblastoma. ACS Nano. 2020;14(8):10127\u201340. https:\/\/doi.org\/10.1021\/acsnano.0c03386","journal-title":"ACS Nano"},{"key":"1947_CR190","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.6b00239","author":"M Stelios Florinas, Liu","year":"2016","unstructured":"Stelios Florinas, Liu M, Fleming R, Van Lilian J, Gilbreth R, et al. Biomacromolecules. 2016;17(5):1818\u201333. https:\/\/doi.org\/10.1021\/acs.biomac.6b00239. A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments."},{"key":"1947_CR191","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2016.11.001","volume":"244","author":"ST Chou","year":"2016","unstructured":"Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, et al. Simultaneous Blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Controlled Release. 2016;244:14\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.001","journal-title":"J Controlled Release"},{"issue":"22","key":"1947_CR192","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/polym15224369","volume":"15","author":"AM Mar\u00eda P\u00e9rez-Ferreiro, Abelairas","year":"2023","unstructured":"Mar\u00eda P\u00e9rez-Ferreiro, Abelairas AM, Criado A, J\u00e9nnifer G\u00f3mez I. Dendrimers: exploring their wide structural variety and applications. Polymers. 2023;15(22):4369\u20139. https:\/\/doi.org\/10.3390\/polym15224369","journal-title":"Polymers"},{"key":"1947_CR193","doi-asserted-by":"crossref","unstructured":"Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GES et al. Dendrimers: A New Race of Pharmaceutical Nanocarriers. BioMed Research International. 2021;2021:e8844030. Available from: https:\/\/www.hindawi.com\/journals\/bmri\/2021\/8844030\/","DOI":"10.1155\/2021\/8844030"},{"issue":"7","key":"1947_CR194","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3109\/21691401.2015.1129625","volume":"44","author":"J Singh","year":"2016","unstructured":"Singh J, Jain K, Mehra NK, Jain NK. Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers. Artif Cells Nanomed Biotechnol. 2016;44(7):1626\u201334. https:\/\/doi.org\/10.3109\/21691401.2015.1129625","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1947_CR195","doi-asserted-by":"publisher","unstructured":"Meltem \u00c7etin E, Aytekin, Yavuz B. Sibel Bozda\u011f-Pehlivan. Nanoscience. Target Brain Drug Delivery. 2017;117\u201347. https:\/\/doi.org\/10.1016\/b978-0-12-803796-6.00007-1","DOI":"10.1016\/b978-0-12-803796-6.00007-1"},{"issue":"9","key":"1947_CR196","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/molecules22091401","volume":"22","author":"L Palmerston Mendes","year":"2017","unstructured":"Palmerston Mendes L, Pan J, Torchilin V. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401. https:\/\/doi.org\/10.3390\/molecules22091401","journal-title":"Molecules"},{"issue":"3","key":"1947_CR197","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/1078-0432.ccr-07-1968","volume":"14","author":"W Yang","year":"2008","unstructured":"Yang W, Wu G, Barth RF, Swindall M, Bandyopadhyaya AK, Tjarks W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-Positive gliomas using boronated monoclonal antibodies. Clin Cancer Res. 2008;14(3):883\u201391. https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-1968","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1947_CR198","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1535-7163.mct-05-0325","volume":"5","author":"G Wu","year":"2006","unstructured":"Wu G. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther. 2006;5(1):52\u20139. https:\/\/doi.org\/10.1158\/1535-7163.mct-05-0325","journal-title":"Mol Cancer Ther"},{"key":"1947_CR199","doi-asserted-by":"publisher","unstructured":"Qin Y, Wang G, Chen L, Sun Y, Yang J, Piao Y, et al. High-Throughput screening of surface engineered cyanine nanodots for active transport of therapeutic antibodies into solid tumor. Adv Mater. 2023;36(9). https:\/\/doi.org\/10.1002\/adma.202302292","DOI":"10.1002\/adma.202302292"},{"issue":"14","key":"1947_CR200","doi-asserted-by":"publisher","first-page":"10142","DOI":"10.1021\/acsnano.3c13088","volume":"18","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhan M, Karpus A, Zou Y, Serge Mignani J-P, Majoral, et al. Brain delivery of biomimetic phosphorus dendrimer\/antibody nanocomplexes for enhanced glioma immunotherapy via immune modulation of T cells and natural killer cells. ACS Nano. 2024;18(14):10142\u201355. https:\/\/doi.org\/10.1021\/acsnano.3c13088","journal-title":"ACS Nano"},{"key":"1947_CR201","doi-asserted-by":"publisher","unstructured":"Jin Z, Piao L, Sun G, Lv C, Jing Y, Jin R. Dual functional nanoparticles efficiently across the blood\u2013brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis. J Drug Target. 2020;1\u201313. https:\/\/doi.org\/10.1080\/1061186x.2020.1841214","DOI":"10.1080\/1061186x.2020.1841214"},{"key":"1947_CR202","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.aca.2012.01.017","volume":"720","author":"MK Admira Bosnjakovic","year":"2012","unstructured":"Admira Bosnjakovic MK, Mishra HJ, Han, Romero R, Kannan RM. A dendrimer-based immunosensor for improved capture and detection of tumor necrosis factor-\u03b1 cytokine. Anal Chim Acta. 2012;720:118\u201325. https:\/\/doi.org\/10.1016\/j.aca.2012.01.017","journal-title":"Anal Chim Acta"},{"issue":"1\u20132","key":"1947_CR203","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijpharm.2013.01.057","volume":"445","author":"CZ Bai","year":"2013","unstructured":"Bai CZ, Choi S, Nam K, An S, Park JS. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int J Pharm. 2013;445(1\u20132):79\u201387. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.01.057","journal-title":"Int J Pharm"},{"key":"1947_CR204","doi-asserted-by":"publisher","unstructured":"Verma G, Rajagopalan MD, Valluru R, Sridhar KA, Nanoparticles. A novel approach to target tumors. Elsevier. 2017;113\u201329. https:\/\/doi.org\/10.1016\/B978-0-323-52727-9.00007-8","DOI":"10.1016\/B978-0-323-52727-9.00007-8"},{"key":"1947_CR205","doi-asserted-by":"publisher","unstructured":"Pathak C, Vaidya FU. Shashibhal Matacharan pandey. Mechanism for development of nanobased drug delivery system. 2019 Jan 1,pp. 35\u201367. https:\/\/doi.org\/10.1016\/b978-0-12-814029-1.00003-x","DOI":"10.1016\/b978-0-12-814029-1.00003-x"},{"issue":"7","key":"1947_CR206","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.progpolymsci.2011.01.001","volume":"36","author":"JP Rao","year":"2011","unstructured":"Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887\u2013913.","journal-title":"Prog Polym Sci"},{"key":"1947_CR207","doi-asserted-by":"publisher","unstructured":"Elkassas D, Arafa A. The innovative applications of therapeutic nanostructures in dentistry. Nanomedicine: Nanotechnology, Biology and Medicine. 2017;13(4):1543\u201362. Available from: https:\/\/doi.org\/10.1016\/j.nano.2017.01.018","DOI":"10.1016\/j.nano.2017.01.018"},{"key":"1947_CR208","doi-asserted-by":"crossref","unstructured":"Hasannia M, Aliabadi A, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Synthesis of block copolymers used in polymersome fabrication: Application in drug delivery. Journal of Controlled Release. 2022;341:95\u2013117. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168365921006052#s0015","DOI":"10.1016\/j.jconrel.2021.11.010"},{"key":"1947_CR209","doi-asserted-by":"publisher","unstructured":"Chu W, Houston ZH, Fletcher NL, Huda P, Ahamed M, Lim TX et al. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic. Biomacromolecules. 2023;24(6):2674\u201390. Available from: https:\/\/doi.org\/10.1021\/acs.biomac.3c00138","DOI":"10.1021\/acs.biomac.3c00138"},{"issue":"11","key":"1947_CR210","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s11095-010-0091-0","volume":"27","author":"R Patil","year":"2010","unstructured":"Patil R, Portilla-Arias J, Ding H, Inoue S, Konda B, Hu J, et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on Poly(\u03b2-L-malic acid). Pharm Res. 2010;27(11):2317\u201329. https:\/\/doi.org\/10.1007\/s11095-010-0091-0","journal-title":"Pharm Res"},{"key":"1947_CR211","doi-asserted-by":"publisher","unstructured":"Juan A, Segrelles C, Almudena del Campo-Balguer\u00edas, Bravo I, Silva I, Peral J et al. Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer. Cancer Nanotechnology. 2023;14(1). https:\/\/doi.org\/10.1186\/s12645-023-00180-z","DOI":"10.1186\/s12645-023-00180-z"},{"issue":"7","key":"1947_CR212","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/02652048.2017.1375039","volume":"34","author":"A Sahin","year":"2017","unstructured":"Sahin A, Digdem Yoyen-Ermis S, Caban-Toktas U, Horzum Y, Aktas, Couvreur P, et al. Evaluation of brain-targeted Chitosan nanoparticles through blood\u2013brain barrier cerebral microvessel endothelial cells. J Microencapsul. 2017;34(7):659\u201366. https:\/\/doi.org\/10.1080\/02652048.2017.1375039","journal-title":"J Microencapsul"},{"key":"1947_CR213","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.pdpdt.2018.06.026","volume":"23","author":"Z Jamali","year":"2018","unstructured":"Jamali Z, Khoobi M, Hejazi SM, Eivazi N, Abdolahpour S, Imanparast F, et al. Evaluation of targeted Curcumin (CUR) loaded PLGA nanoparticles for in vitro photodynamic therapy on human glioblastoma cell line. Photodiagn Photodyn Ther. 2018;23:190\u2013201. https:\/\/doi.org\/10.1016\/j.pdpdt.2018.06.026","journal-title":"Photodiagn Photodyn Ther"},{"key":"1947_CR214","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.jddst.2020.102039","volume":"60","author":"M Hassanzadeganroudsari","year":"2020","unstructured":"Hassanzadeganroudsari M, Soltani M, Heydarinasab A, Apostolopoulos V, Akbarzadehkhiyavi A, Nurgali K. Targeted nano-drug delivery system for glioblastoma therapy: in vitro and in vivo study. J Drug Deliv Sci Technol. 2020;60:102039. https:\/\/doi.org\/10.1016\/j.jddst.2020.102039","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"1947_CR215","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s13346-020-00824-2","volume":"10","author":"NN Ferreira","year":"2020","unstructured":"Ferreira NN, Granja S, Boni FI, Prezotti FG, Ferreira LMB, Cury BSF, et al. Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route. Drug Delivery Translational Res. 2020;10(6):1729\u201347. https:\/\/doi.org\/10.1007\/s13346-020-00824-2","journal-title":"Drug Delivery Translational Res"},{"key":"1947_CR216","doi-asserted-by":"publisher","first-page":"118361","DOI":"10.1016\/j.lfs.2020.118361","volume":"261","author":"N Eivazi","year":"2020","unstructured":"Eivazi N, Rahmani R, Paknejad M. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody. Life Sci. 2020;261:118361. https:\/\/doi.org\/10.1016\/j.lfs.2020.118361","journal-title":"Life Sci"},{"issue":"2","key":"1947_CR217","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellimm.2014.01.003","volume":"287","author":"M Chen","year":"2014","unstructured":"Chen M, Ouyang H, Zhou S, Li J, Ye Y. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Cell Immunol. 2014;287(2):91\u20139. https:\/\/doi.org\/10.1016\/j.cellimm.2014.01.003","journal-title":"Cell Immunol"},{"key":"1947_CR218","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2022.06.048","volume":"349","author":"N Kaeokhamloed","year":"2022","unstructured":"Kaeokhamloed N, Legeay S, Roger E. FRET as the tool for in vivo nanomedicine tracking. J Controlled Release. 2022;349:156\u201373. https:\/\/doi.org\/10.1016\/j.jconrel.2022.06.048","journal-title":"J Controlled Release"},{"key":"1947_CR219","doi-asserted-by":"publisher","unstructured":"Victoria J, Tripathi S, Prakash V, Tiwari K, Shivani Mahra, Sharma A et al. Encapsulated nanopesticides application in plant protection: quo vadis? Plant physiology and biochemistry. 2023;206:108225\u20135. https:\/\/doi.org\/10.1016\/j.plaphy.2023.108225","DOI":"10.1016\/j.plaphy.2023.108225"},{"key":"1947_CR220","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymeth.2021.07.009","volume":"199","author":"AL Lima","year":"2022","unstructured":"Lima AL, Gratieri T, Cunha-Filho M, Gelfuso GM. Polymeric nanocapsules: A review on design and production methods for pharmaceutical purpose. Methods. 2022;199:54\u201366. https:\/\/doi.org\/10.1016\/j.ymeth.2021.07.009","journal-title":"Methods"},{"issue":"5","key":"1947_CR221","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/nano10050847","volume":"10","author":"S Deng","year":"2020","unstructured":"Deng S, Gigliobianco MR, Censi R, Di Martino P. Polymeric nanocapsules as Nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials. 2020;10(5):847. https:\/\/doi.org\/10.3390\/nano10050847","journal-title":"Nanomaterials"},{"issue":"2","key":"1947_CR222","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jconrel.2007.06.019","volume":"122","author":"Y Tsutsui","year":"2007","unstructured":"Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T, Ohmori I, et al. Development of bionanocapsules targeting brain tumors. J Controlled Release. 2007;122(2):159\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2007.06.019","journal-title":"J Controlled Release"},{"key":"1947_CR223","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.4137\/cmwh.s8213","volume":"6","author":"H Hamada","year":"2013","unstructured":"Hamada H, Shimoda K, Seno M. Chemo-enzymatic synthesis of Propionyl-ester-linked Taxol-monosaccharide conjugate and its drug delivery system using Hybrid-Bio-nanocapsules targeting brain glioma cells. Clin Med Insights Women S Health. 2013;6:8213\u20133. https:\/\/doi.org\/10.4137\/cmwh.s8213. CMWH.S.","journal-title":"Clin Med Insights Women S Health"},{"issue":"20","key":"1947_CR224","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2217\/nnm-2021-0169","volume":"16","author":"CS de Alves","year":"2021","unstructured":"de Alves CS, Lavayen A, de Fraga Dias V, Bruinsmann A, Scholl FA, C\u00e9 JN. EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: A Nose-To-Brain multitarget approach against glioblastoma. Nanomedicine. 2021;16(20):1775\u201390. https:\/\/doi.org\/10.2217\/nnm-2021-0169","journal-title":"Nanomedicine"},{"issue":"2","key":"1947_CR225","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/gels7020063","volume":"7","author":"B Stawicki","year":"2021","unstructured":"Stawicki B, Schacher T, Cho H. Nanogels as a versatile drug delivery system for brain cancer. Gels. 2021;7(2):63. https:\/\/doi.org\/10.3390\/gels7020063","journal-title":"Gels"},{"key":"1947_CR226","doi-asserted-by":"crossref","unstructured":"Soni KS, Desale SS, Bronich TK. Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation. Journal of controlled release: official journal of the Controlled Release Society. 2016;240:109\u201326. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4862943\/","DOI":"10.1016\/j.jconrel.2015.11.009"},{"issue":"11","key":"1947_CR227","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.7150\/thno.23459","volume":"8","author":"W Wu","year":"2018","unstructured":"Wu W, Luo L, Wang Y, Wu Q, Dai HB, Li JS, et al. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. Theranostics. 2018;8(11):3038\u201358.","journal-title":"Theranostics"},{"key":"1947_CR228","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jcis.2019.11.109","volume":"561","author":"SC Liao","year":"2020","unstructured":"Liao SC, Ting CW, Chiang W. Functionalized polymeric nanogels with pH-sensitive benzoic-imine cross-linkages designed as vehicles for indocyanine green delivery. J Colloid Interface Sci. 2020;561:11\u201322. https:\/\/doi.org\/10.1016\/j.jcis.2019.11.109","journal-title":"J Colloid Interface Sci"},{"key":"1947_CR229","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eurpolymj.2018.02.016","volume":"101","author":"ES Kang","year":"2018","unstructured":"Kang ES, Lee G, In I. pH-sensitive fluorescent hyaluronic acid nanogels for tumor-targeting and controlled delivery of doxorubicin and nitric oxide. Eur Polymer J. 2018;101:96\u2013104. https:\/\/doi.org\/10.1016\/j.eurpolymj.2018.02.016","journal-title":"Eur Polymer J"},{"key":"1947_CR230","doi-asserted-by":"publisher","unstructured":"Manimaran V, Nivetha R, Tamilanban T, Narayanan J, Vetriselvan Subramaniyan NK, Fuloria, et al. Nanogels as novel drug nanocarriers for CNS drug delivery. Front Mol Biosci. 2023;10. https:\/\/doi.org\/10.3389\/fmolb.2023.1232109","DOI":"10.3389\/fmolb.2023.1232109"},{"issue":"3","key":"1947_CR231","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.reactfunctpolym.2010.10.011","volume":"71","author":"NV Nukolova","year":"2011","unstructured":"Nukolova NV, Yang Z, Kim JO, Kabanov AV, Bronich TK. Polyelectrolyte nanogels decorated with monoclonal antibody for targeted drug delivery. Reactive Funct Polym. 2011;71(3):315\u201323. https:\/\/doi.org\/10.1016\/j.reactfunctpolym.2010.10.011","journal-title":"Reactive Funct Polym"},{"key":"1947_CR232","doi-asserted-by":"publisher","unstructured":"Liu R, Liang Q, Luo J, Li Y, Zhang X, Fan K, et al. Ferritin-Based nanocomposite hydrogel promotes tumor penetration and enhances cancer chemoimmunotherapy. Adv Sci. 2023;11(3). https:\/\/doi.org\/10.1002\/advs.202305217","DOI":"10.1002\/advs.202305217"},{"key":"1947_CR233","doi-asserted-by":"crossref","unstructured":"Pallavi P, Harini K, Gowtham P, Girigoswami K, Girigoswami A. Fabrication of Polymersomes: A Macromolecular Architecture in Nanotherapeutics. Chemistry. 2022;4(3):1028\u201343. Available from: https:\/\/www.mdpi.com\/2624-8549\/4\/3\/70https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10817611\/","DOI":"10.3390\/chemistry4030070"},{"key":"1947_CR234","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jconrel.2020.12.027","volume":"330","author":"F Araste","year":"2021","unstructured":"Araste F, Aliabadi A, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Self-assembled polymeric vesicles: focus on polymersomes in cancer treatment. J Controlled Release. 2021;330:502\u201328. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.027","journal-title":"J Controlled Release"},{"key":"1947_CR235","doi-asserted-by":"crossref","unstructured":"Fonseca M, Jarak I, Victor F, Domingues C, Veiga F, Figueiras A. Polymersomes as the Next Attractive Generation of Drug Delivery Systems: Definition, Synthesis and Applications. Materials. 2024;17(2):319. Available from: https:\/\/www.mdpi.com\/1996-1944\/17\/2\/319","DOI":"10.3390\/ma17020319"},{"key":"1947_CR236","doi-asserted-by":"publisher","unstructured":"Bobde SS. Polymersomes for targeting to brain tumors. Elsevier. 2022;451\u201381. https:\/\/doi.org\/10.1016\/B978-0-323-90773-6.00013-0","DOI":"10.1016\/B978-0-323-90773-6.00013-0"},{"issue":"34","key":"1947_CR237","doi-asserted-by":"publisher","first-page":"9144","DOI":"10.1016\/j.biomaterials.2011.08.036","volume":"32","author":"JS Lee","year":"2011","unstructured":"Lee JS, Groothuis T, Cusan C, Mink D, Feijen J. Lysosomally cleavable peptide-containing polymersomes modified with anti-EGFR antibody for systemic cancer chemotherapy. Biomaterials. 2011;32(34):9144\u201353. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.08.036","journal-title":"Biomaterials"},{"key":"1947_CR238","doi-asserted-by":"crossref","unstructured":"von Witting E, Hober S, Kanje S. Affinity-Based Methods for Site-Specific Conjugation of Antibodies. Bioconjugate Chemistry. 2021;32(8):1515\u201324. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8377709\/","DOI":"10.1021\/acs.bioconjchem.1c00313"},{"key":"1947_CR239","doi-asserted-by":"crossref","unstructured":"Ma H, \u00d3\u2019F\u00e1g\u00e1in C, O\u2019Kennedy R. Antibody stability: A key to performance - Analysis, influences and improvement. Biochimie. 2020;177:213\u201325. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0300908420302054","DOI":"10.1016\/j.biochi.2020.08.019"},{"key":"1947_CR240","doi-asserted-by":"publisher","unstructured":"Zhang Q, Liang J, Bongers A, Richardson JJ, Liang K, Gu Z. Site-Specific antibody assembly on nanoparticles via a versatile coating method for improved cell targeting. Adv Sci. 2023;10(9). https:\/\/doi.org\/10.1002\/advs.202206546","DOI":"10.1002\/advs.202206546"},{"key":"1947_CR241","doi-asserted-by":"publisher","unstructured":"Robertson JD, Rizzello L, Avila-Olias M, Gaitzsch J, Contini C, Mago\u0144 MS et al. Purification of Nanoparticles by Size and Shape. Scientific Reports. 2016;6(1). https:\/\/doi.org\/10.1038\/srep27494","DOI":"10.1038\/srep27494"},{"key":"1947_CR242","doi-asserted-by":"publisher","unstructured":"Chen C, Garcia Z, Chen D, Liu H, Trelstad P. Cost and supply considerations for antibody therapeutics. mAbs. 2025;17(1). Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/19420862.2025.2451789","DOI":"10.1080\/19420862.2025.2451789"},{"key":"1947_CR243","doi-asserted-by":"crossref","unstructured":"Rajan R, Ahmed S, Sharma N, Kumar N, Debas A, Matsumura K. Review of the current state of protein aggregation inhibition from a materials chemistry perspective: special focus on polymeric materials. Materials Advances. 2021;2(4):1139\u201376. Available from: https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2021\/ma\/d0ma00760a","DOI":"10.1039\/D0MA00760A"},{"key":"1947_CR244","doi-asserted-by":"publisher","unstructured":"Ngamcherdtrakul W, Sangvanich T, Reda M, Gu S, Bejan D, Yantasee W. Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for SiRNA delivery. Int J Nanomed 2018;Volume 13:4015\u201327. https:\/\/doi.org\/10.2147\/IJN.S164393","DOI":"10.2147\/IJN.S164393"},{"key":"1947_CR245","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jconrel.2021.06.042","volume":"336","author":"A Merivaara","year":"2021","unstructured":"Merivaara A, Zini J, Koivunotko E, Valkonen S, Korhonen O, Fernandes FM, et al. Preservation of biomaterials and cells by freeze-drying: change of paradigm. J Controlled Release. 2021;336:480\u201398. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.042","journal-title":"J Controlled Release"},{"issue":"1\u20132","key":"1947_CR246","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijpharm.2018.08.045","volume":"550","author":"MA Hamaly","year":"2018","unstructured":"Hamaly MA, Abulateefeh SR, Al-Qaoud KM, Alkilany AM. Freeze-drying of monoclonal antibody-conjugated gold nanorods: colloidal stability and biological activity. Int J Pharm. 2018;550(1\u20132):269\u201377. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.08.045","journal-title":"Int J Pharm"},{"key":"1947_CR247","doi-asserted-by":"crossref","unstructured":"Lihui X, Zhao J, Skonieczna M, Zhou P, Huang R. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm. 2023;4(4). Doi.","DOI":"10.1002\/mco2.327"},{"issue":"5","key":"1947_CR248","doi-asserted-by":"publisher","first-page":"e2409945","DOI":"10.1002\/adma.202409945","volume":"37","author":"MH Zaleski","year":"2025","unstructured":"Zaleski MH, Chase LS, Hood ED, Wang Z, Nong J, Espy CL, et al. Conjugation chemistry markedly impacts toxicity and biodistribution of targeted nanoparticles, mediated by complement activation. Adv Mater. 2025;37(5):e2409945. https:\/\/doi.org\/10.1002\/adma.202409945","journal-title":"Adv Mater"},{"key":"1947_CR249","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Zhou S, Ota Y, Harrington M, Miyagi E, Takagi H et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectrum. 2023 Aug 31 [cited 2023 Dec 11];7(5). Available from: https:\/\/academic.oup.com\/jncics\/article\/7\/5\/pkad069\/7282992#","DOI":"10.1093\/jncics\/pkad069"},{"key":"1947_CR250","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jconrel.2017.11.026","volume":"269","author":"JS Kim","year":"2018","unstructured":"Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Controlled Release. 2018;269:245\u201357. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.026","journal-title":"J Controlled Release"},{"issue":"5","key":"1947_CR251","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s11095-013-1249-3","volume":"31","author":"E Markoutsa","year":"2013","unstructured":"Markoutsa E, Papadia K, Giannou AD, Spella M, Cagnotto A, Salmona M, et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm Res. 2013;31(5):1275\u201389. https:\/\/doi.org\/10.1007\/s11095-013-1249-3","journal-title":"Pharm Res"},{"key":"1947_CR252","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2019.01.005","volume":"295","author":"KB Johnsen","year":"2019","unstructured":"Johnsen KB, Bak M, Melander F, Thomsen MS, Burkhart A, Kempen PJ, et al. Modulating the antibody density changes the uptake and transport at the BBB of both transferrin receptor-targeted gold nanoparticles and liposomal cargo. J Controlled Release. 2019;295:237\u201349. https:\/\/doi.org\/10.1016\/j.jconrel.2019.01.005","journal-title":"J Controlled Release"},{"key":"1947_CR253","doi-asserted-by":"crossref","unstructured":"Kuo YC, Lee CH. Dual targeting of solid lipid nanoparticles grafted with 83\u2013\u200914 MAb and anti-EGF receptor for malignant brain tumor therapy. Life Sciences. 2016;146:222\u201331. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0024320516300248?via%3Dihub","DOI":"10.1016\/j.lfs.2016.01.025"},{"issue":"4","key":"1947_CR254","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s42247-019-00033-9","volume":"2","author":"GB Heggannavar","year":"2019","unstructured":"Heggannavar GB, Vijeth S, Kariduraganavar MY. Preparation of transferrin-conjugated poly-\u03b5-caprolactone nanoparticles and delivery of Paclitaxel to treat glioblastoma across blood\u2013brain barrier. Emergent Mater. 2019;2(4):463\u201374. https:\/\/doi.org\/10.1007\/s42247-019-00033-9","journal-title":"Emergent Mater"},{"issue":"8","key":"1947_CR255","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, Alomari S, Tyler BM. Crossing the BBB: advances in nanoparticle technology for drug delivery in Neuro-Oncology. Int J Mol Sci. 2022;23(8):4153. https:\/\/doi.org\/10.3390\/ijms23084153","journal-title":"Int J Mol Sci"},{"key":"1947_CR256","doi-asserted-by":"crossref","unstructured":"Anraku Y, Kuwahara H, Fukusato Y, Mizoguchi A, Ishii T, Nitta K et al. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nature Communications. 2017 Oct 17 [cited 2021 May 31];8(1):1001. Available from: https:\/\/www.nature.com\/articles\/s41467-017-00952-3","DOI":"10.1038\/s41467-017-00952-3"},{"key":"1947_CR257","doi-asserted-by":"crossref","unstructured":"Stankovi\u0107 T, Ran\u0111elovi\u0107 T, Dragoj M, Stojkovi\u0107 Buri\u0107 S, Fern\u00e1ndez L, Ochoa I et al. In vitro biomimetic models for glioblastoma-a promising tool for drug response studies. Drug Resistance Updates. 2021;55:100753. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S136876462100011X","DOI":"10.1016\/j.drup.2021.100753"},{"issue":"12","key":"1947_CR258","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","volume":"12","author":"B Pinto","year":"2020","unstructured":"Pinto B, Henriques AC, Silva PMA, Bousbaa H. Three-Dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics. 2020;12(12):1186. https:\/\/doi.org\/10.3390\/pharmaceutics12121186","journal-title":"Pharmaceutics"},{"key":"1947_CR259","doi-asserted-by":"crossref","unstructured":"Asimakidou E, Tan JKS, Zeng J, Lo CH. Blood\u2013Brain Barrier-Targeting Nanoparticles: Biomaterial Properties and Biomedical Applications in Translational Neuroscience. Pharmaceuticals. 2024;17(5):612. Available from: https:\/\/www.mdpi.com\/1424-8247\/17\/5\/612","DOI":"10.3390\/ph17050612"},{"key":"1947_CR260","unstructured":"National Cancer Institute. Current Nanotechnology Treatments. National Cancer Institute. Cancer.gov. 2017. Available from: https:\/\/www.cancer.gov\/nano\/cancer-nanotechnology\/current-treatments"},{"key":"1947_CR261","doi-asserted-by":"crossref","unstructured":"Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA oncology. 2018 Oct 1 [cited 2020 Oct 30];4(10):1344\u201351. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29978216\/","DOI":"10.1001\/jamaoncol.2018.2168"},{"key":"1947_CR262","doi-asserted-by":"publisher","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomedicine & Pharmacotherapy. 2023;161:114408. Available from: https:\/\/doi.org\/10.1016\/j.biopha.2023.114408","DOI":"10.1016\/j.biopha.2023.114408"},{"key":"1947_CR263","doi-asserted-by":"publisher","unstructured":"Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CB et al. A Polymer-Based Antibody\u2013Vinca drug conjugate platform: characterization and preclinical efficacy. 2015;75(16):3365\u201372. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0129","DOI":"10.1158\/0008-5472.CAN-15-0129"},{"issue":"8","key":"1947_CR264","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","volume":"9","author":"CM Mckertish","year":"2021","unstructured":"Mckertish CM, Kayser V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines. 2021;9(8):872. https:\/\/doi.org\/10.3390\/biomedicines9080872","journal-title":"Biomedicines"},{"key":"1947_CR265","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","volume":"337","author":"T Tedeschini","year":"2021","unstructured":"Tedeschini T, Campara B, Grigoletto A, Bellini M, Salvalaio M, Matsuno Y, et al. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Controlled Release. 2021;337:431\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.041","journal-title":"J Controlled Release"},{"issue":"2","key":"1947_CR266","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.progpolymsci.2013.09.003","volume":"39","author":"A Srivastava","year":"2014","unstructured":"Srivastava A, O\u2019Connor IB, Pandit A, Gerard Wall J. Polymer-antibody fragment conjugates for biomedical applications. Prog Polym Sci. 2014;39(2):308\u201329. https:\/\/doi.org\/10.1016\/j.progpolymsci.2013.09.003","journal-title":"Prog Polym Sci"},{"issue":"8","key":"1947_CR267","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1021\/acs.biomac.3c00385","volume":"24","author":"K Pintu Kanjilal, Singh","year":"2023","unstructured":"Pintu Kanjilal, Singh K, Das R, Matte J. Thayumanavan. Antibody polymer conjugates (APCs) for active targeted therapeutic delivery. Biomacromolecules. 2023;24(8):3638\u201346. https:\/\/doi.org\/10.1021\/acs.biomac.3c00385","journal-title":"Biomacromolecules"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01947-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:12:59Z","timestamp":1781604779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01947-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":267,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01947-0","relation":{"references":[{"id-type":"doi","id":"10.1021\/acs.biomac.6b00239","asserted-by":"subject"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}